Inpharmatica secures ADME service agreement with Ionix Pharmaceuticals

Informatics-driven drug discovery company Inpharmatica has entered into a non-exclusive ADME service agreement with Ionix Pharmaceuticals, the European analgesic drug discovery company.

The announcement is in line with the company's plans to acquire research capabilities in ADME through the purchase of labs, licensing of intellectual property and employment of an experienced ADME team.

Under the terms of the agreement, Inpharmatica and Ionix will collaborate on the generation of in vitro and pharmacokinetic ADME data for certain Ionix product development programmes.

'This agreement demonstrates the value of Inpharmatica's combination of experience in lead optimisation, application of its in silico tools, and ADME laboratory facilities in Cambridge. Inpharmatica's service means that biotech companies like Ionix can focus their internal resources on their novel approaches to drug discovery, while accessing state-of-the-art lead optimisation support,' said Dr Mike Tarbit, senior vice president - preclinical r&d at Inpharmatica.

Inpharmatica's flagship technology platform is PharmaCarta, a computational chemogenomics system that links genomic and proteomic space with chemistry and provides a unique approach to hit identification and lead generation and optimisation for druggable targets.

The company's ADME and chemistry facilities are located on the Cambridge Science Park and provide support for the company's internal discovery programs as well as contract ADME services.